• Molecular NameCefmenoxime
  • SynonymCefmenoxima [INN-Spanish]; Cefmenoxime hydrochloride; Cefmenoximum [INN-Latin]
  • Weight511.568
  • Drugbank_IDDB00267
  • ACS_NO65085-01-0
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-0.42
  • pkaN/A
  • LogD (pH=7, predicted)-4.4
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.91
  • LogSw (predicted, AB/LogsW2.0)2.85
  • Sw (mg/ml) (predicted, ACD/Labs)0.04
  • No.of HBond Donors4
  • No.of HBond Acceptors14
  • No.of Rotatable Bonds8
  • TPSA269.65
  • StatusFDA approved
  • AdministrationIntramuscular, intravenous
  • PharmacologyA third-generation cephalosporin antibiotic.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding60.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNegligible
  • Half life1 h
  • ExcretionRenal, unchanged
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityInformation on cefmenoxime overdosage in humans is not available. However, with other b-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A